Literature DB >> 8087445

Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.

A Moran-Ribon1, J P Droz, J Kattan, B Leclercq, M Ghosn, D Couanet, M Ostronoff, S Culine, B Misset, B Escudier.   

Abstract

Among patients suffering from nonseminomatous germ-cell tumor, with a poor prognosis, a subset underwent respiratory failure and died very early in the course of their treatment. Between 1982 and 1989, 11 out of 56 such patients (20%) died within the first 5 weeks of chemotherapy. The clinical, radiological, biological and infectious characteristics of these patients were analyzed. Nine patients had extensive pulmonary metastases and the 2 others presented a bulky mediastinal mass with pleural effusion. All patients experienced acute respiratory distress during chemotherapy and underwent mechanical ventilation. All patients were febrile, and septicemia was documented in 7 cases. WHO grade 4 and grade 1-2 renal toxicities occurred in 3 and 4 patients respectively. There was no tumor lysis syndrome. All patients died within 35 days from the start of therapy; 4 were autopsied. These 11 patients represent a clinical entity, having what we called super-high-risk germ cell tumors. Early death is related to pulmonary distress within the first 5 weeks of therapy. The origin of the pulmonary distress is multifactorial: bulky disease of the chest, infection, and interstitial fibrosis. Immediate full-dose standard chemotherapy in association with intensive supportive care is recommended in the management of these patients.

Entities:  

Mesh:

Year:  1994        PMID: 8087445     DOI: 10.1007/bf00365732

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

1.  Current optimum management of anaplastic germ cell tumours of the testis and other sites.

Authors:  E S Newlands; K D Bagshawe; R H Begent; G J Rustin; S M Crawford; L Holden
Journal:  Br J Urol       Date:  1986-06

2.  Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients.

Authors:  C J Logothetis; M L Samuels; D E Selig; S Ogden; F Dexeus; D Swanson; D Johnson; A von Eschenbach
Journal:  Am J Med       Date:  1986-08       Impact factor: 4.965

3.  Pulmonary hemorrhage with diffuse alveolar infiltrates in men with high-volume choriocarcinoma.

Authors:  J O Benditt; H W Farber; J Wright; A B Karnad
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

4.  Fatal respiratory failure following chemotherapy of advanced teratoma--a pulmonary tumour lysis syndrome?

Authors:  J H Phipps; F J Madden; P A Shaw
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

5.  Treatment of testicular cancer: a new and improved model.

Authors:  L H Einhorn
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

6.  Prognostic factors for favorable outcome in disseminated germ cell tumors.

Authors:  R Birch; S Williams; A Cone; L Einhorn; P Roark; S Turner; F A Greco
Journal:  J Clin Oncol       Date:  1986-03       Impact factor: 44.544

7.  A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors.

Authors:  J P Droz; J L Pico; M Ghosn; A Kramar; A Rey; M Ostronoff; D Baume
Journal:  Bull Cancer       Date:  1992       Impact factor: 1.276

8.  Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis.

Authors:  J P Droz; A Kramar; M Ghosn; G Piot; A Rey; C Theodore; P Wibault; B H Court; J L Perrin; J P Travagli
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

9.  A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

Authors:  G J Bosl; N L Geller; D Bajorin; S P Leitner; A Yagoda; R B Golbey; H Scher; N J Vogelzang; J Auman; R Carey
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

10.  Acute tumor lysis syndrome in poor-risk germ cell tumors: does it exist?

Authors:  J Kattan; S Culine; T Tavakoli-Razavi; A Kramar; J P Droz
Journal:  Support Care Cancer       Date:  1994-03       Impact factor: 3.603

View more
  5 in total

Review 1.  Chemotherapy-related acute respiratory distress syndrome in germ cell tumors: a literature review.

Authors:  Mohamed Alsharedi; Nabiha Elmsherghi; Maria Monica Haydock; Hazim Bukamur
Journal:  Med Oncol       Date:  2017-03-04       Impact factor: 3.064

2.  Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.

Authors:  Alexey Tryakin; Mikhail Fedyanin; Anatoly Bulanov; Shalva Kashia; Ildar Kurmukov; Vsevolod Matveev; Igor Fainstein; Olga Gordeeva; Tatjana Zakharova; Sergei Tjulandin
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-05       Impact factor: 4.553

3.  Acute respiratory distress syndrome after chemotherapy for lung metastases from non-seminomatous germ-cell tumors.

Authors:  C Kirch; F Blot; K Fizazi; B Raynard; C Theodore; G Nitenberg
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

4.  Testicular Germ Cell Tumors: Paraneoplastic Syndromes and the Role of Beta-Human Chorionic Gonadotropin.

Authors:  Toufic Tannous; John Miskovsky; Matthew Keating
Journal:  Cureus       Date:  2021-04-04

5.  Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors.

Authors:  Katarina Rejlekova; Katarina Kalavska; Marek Makovnik; Nikola Hapakova; Michal Chovanec; Valentina De Angelis; Jana Obertova; Patrik Palacka; Zuzana Sycova-Mila; Jozef Mardiak; Michal Mego
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.